Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H.Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg

Research output: Contribution to journalArticlepeer-review

83 Scopus citations
Original languageEnglish (US)
Pages (from-to)2866-2870
Number of pages5
JournalBlood Advances
Issue number13
StatePublished - Jul 14 2020

ASJC Scopus subject areas

  • Hematology

Cite this